Is Eledon Pharmaceuticals Stock a Good Investment?
Eledon Pharmaceuticals Investment Advice | ELDN |
- Examine Eledon Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Eledon Pharmaceuticals' leadership team and their track record. Good management can help Eledon Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Eledon Pharmaceuticals' business and its evolving consumer preferences.
- Compare Eledon Pharmaceuticals' performance and market position to its competitors. Analyze how Eledon Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Eledon Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Eledon Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Eledon Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Eledon Pharmaceuticals is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Eledon Pharmaceuticals Stock
Researching Eledon Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 43.0% of the company shares are held by institutions such as insurance companies. The book value of Eledon Pharmaceuticals was currently reported as 1.85. The company has Price/Earnings To Growth (PEG) ratio of 0.01. Eledon Pharmaceuticals last dividend was issued on the 5th of October 2020. The entity had 1:18 split on the 5th of October 2020.
To determine if Eledon Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Eledon Pharmaceuticals' research are outlined below:
| Eledon Pharmaceuticals generated a negative expected return over the last 90 days | |
| Eledon Pharmaceuticals has high historical volatility and very poor performance | |
| Eledon Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (116.54 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Eledon Pharmaceuticals currently holds about 70.46 M in cash with (39.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.12, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Eledon Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by Bvf Partners L Pil of 1031385 shares of Eledon Pharmaceuticals at 2.37 subject to Rule 16b-3 |
Eledon Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Eledon Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Eledon Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Eledon Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Eledon Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Eledon Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-08-10 | 2023-06-30 | -0.46 | -0.4 | 0.06 | 13 | ||
2021-08-12 | 2021-06-30 | -0.57 | -0.5 | 0.07 | 12 | ||
2024-03-28 | 2023-12-31 | -0.39 | -0.29 | 0.1 | 25 | ||
2023-11-09 | 2023-09-30 | -0.46 | -0.35 | 0.11 | 23 | ||
2023-05-11 | 2023-03-31 | -0.6 | -0.75 | -0.15 | 25 | ||
2022-03-24 | 2021-12-31 | -0.75 | -0.59 | 0.16 | 21 | ||
2021-05-13 | 2021-03-31 | -0.32 | -0.57 | -0.25 | 78 | ||
2020-05-15 | 2020-03-31 | -2.88 | -3.42 | -0.54 | 18 |
Eledon Pharmaceuticals Target Price Consensus
Eledon target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Eledon Pharmaceuticals' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 6 | Strong Buy |
Most Eledon analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Eledon stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Eledon Pharmaceuticals, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationEledon Pharmaceuticals Target Price Projection
Eledon Pharmaceuticals' current and average target prices are 4.52 and 12.50, respectively. The current price of Eledon Pharmaceuticals is the price at which Eledon Pharmaceuticals is currently trading. On the other hand, Eledon Pharmaceuticals' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Eledon Pharmaceuticals Market Quote on 3rd of February 2025
Target Price
Analyst Consensus On Eledon Pharmaceuticals Target Price
Eledon Pharmaceuticals Analyst Ratings
Eledon Pharmaceuticals' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Eledon Pharmaceuticals stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Eledon Pharmaceuticals' financials, market performance, and future outlook by experienced professionals. Eledon Pharmaceuticals' historical ratings below, therefore, can serve as a valuable tool for investors.Know Eledon Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Eledon Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Eledon Pharmaceuticals backward and forwards among themselves. Eledon Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Eledon Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Cm Management, Llc | 2024-09-30 | 275 K | Blackrock Inc | 2024-09-30 | 215.9 K | Cwm Advisors, Llc | 2024-12-31 | 194.7 K | State Street Corp | 2024-09-30 | 161.5 K | Renaissance Technologies Corp | 2024-09-30 | 135.9 K | Northern Trust Corp | 2024-09-30 | 91.9 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 83.5 K | Ingalls & Snyder Llc | 2024-12-31 | 51.8 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 34.2 K | Bvf Inc | 2024-09-30 | 6.3 M | Armistice Capital, Llc | 2024-09-30 | 2.4 M |
Eledon Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 270.02 M.Market Cap |
|
Eledon Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.82) | (0.86) | |
| Return On Capital Employed | (0.45) | (0.48) | |
| Return On Assets | (0.41) | (0.43) | |
| Return On Equity | (6.43) | (6.11) |
Determining Eledon Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Eledon Pharmaceuticals is a good buy. For example, gross profit margin measures Eledon Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Eledon Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Eledon Pharmaceuticals' management efficiency
Eledon Pharmaceuticals has return on total asset (ROA) of (0.3336) % which means that it has lost $0.3336 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2536) %, meaning that it created substantial loss on money invested by shareholders. Eledon Pharmaceuticals' management efficiency ratios could be used to measure how well Eledon Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 3rd of February 2025, Return On Tangible Assets is likely to drop to -0.86. In addition to that, Return On Capital Employed is likely to drop to -0.48. At this time, Eledon Pharmaceuticals' Non Currrent Assets Other are very stable compared to the past year. As of the 3rd of February 2025, Other Current Assets is likely to grow to about 6.1 M, while Total Assets are likely to drop about 82.4 M.| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | 0.24 | 0.25 | |
| Price Book Value Ratio | 5.5 K | 5.8 K | |
| Enterprise Value Multiple | 0.24 | 0.25 | |
| Price Fair Value | 5.5 K | 5.8 K | |
| Enterprise Value | -26.6 M | -25.2 M |
Management at Eledon Pharmaceuticals focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Beta 0.766 |
Basic technical analysis of Eledon Stock
As of the 3rd of February, Eledon Pharmaceuticals shows the Downside Deviation of 4.36, mean deviation of 4.09, and Coefficient Of Variation of 937.63. Eledon Pharmaceuticals technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Eledon Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Eledon Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Eledon Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Eledon Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Eledon Pharmaceuticals' Outstanding Corporate Bonds
Eledon Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Eledon Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Eledon bonds can be classified according to their maturity, which is the date when Eledon Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| ELEMENT SOLUTIONS INC Corp BondUS28618MAA45 | View |
Understand Eledon Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Eledon Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0979 | |||
| Market Risk Adjusted Performance | 0.8229 | |||
| Mean Deviation | 4.09 | |||
| Semi Deviation | 4.1 | |||
| Downside Deviation | 4.36 | |||
| Coefficient Of Variation | 937.63 | |||
| Standard Deviation | 5.42 | |||
| Variance | 29.34 | |||
| Information Ratio | 0.0921 | |||
| Jensen Alpha | 0.5197 | |||
| Total Risk Alpha | 0.1241 | |||
| Sortino Ratio | 0.1145 | |||
| Treynor Ratio | 0.8129 | |||
| Maximum Drawdown | 28.12 | |||
| Value At Risk | (6.84) | |||
| Potential Upside | 10.98 | |||
| Downside Variance | 19.0 | |||
| Semi Variance | 16.83 | |||
| Expected Short fall | (5.07) | |||
| Skewness | 0.6805 | |||
| Kurtosis | 0.7867 |
| Risk Adjusted Performance | 0.0979 | |||
| Market Risk Adjusted Performance | 0.8229 | |||
| Mean Deviation | 4.09 | |||
| Semi Deviation | 4.1 | |||
| Downside Deviation | 4.36 | |||
| Coefficient Of Variation | 937.63 | |||
| Standard Deviation | 5.42 | |||
| Variance | 29.34 | |||
| Information Ratio | 0.0921 | |||
| Jensen Alpha | 0.5197 | |||
| Total Risk Alpha | 0.1241 | |||
| Sortino Ratio | 0.1145 | |||
| Treynor Ratio | 0.8129 | |||
| Maximum Drawdown | 28.12 | |||
| Value At Risk | (6.84) | |||
| Potential Upside | 10.98 | |||
| Downside Variance | 19.0 | |||
| Semi Variance | 16.83 | |||
| Expected Short fall | (5.07) | |||
| Skewness | 0.6805 | |||
| Kurtosis | 0.7867 |
Consider Eledon Pharmaceuticals' intraday indicators
Eledon Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Eledon Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Eledon Pharmaceuticals Corporate Filings
F4 | 13th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 20th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 5th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Eledon Stock media impact
Far too much social signal, news, headlines, and media speculation about Eledon Pharmaceuticals that are available to investors today. That information is available publicly through Eledon media outlets and privately through word of mouth or via Eledon internal channels. However, regardless of the origin, that massive amount of Eledon data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Eledon Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Eledon Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Eledon Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Eledon Pharmaceuticals alpha.
Eledon Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Eledon Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Eledon Pharmaceuticals Corporate Management
| Gregory Flesher | Consultant | Profile | |
| Bryan JD | Corporate Counsel | Profile | |
| John Herberger | Vice Operations | Profile | |
| Paul Little | Chief Officer | Profile | |
| David Hovland | Chief Officer | Profile | |
| FACS FACS | Chief Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eledon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eledon Pharmaceuticals. If investors know Eledon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eledon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Eledon Pharmaceuticals is measured differently than its book value, which is the value of Eledon that is recorded on the company's balance sheet. Investors also form their own opinion of Eledon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eledon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eledon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eledon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Eledon Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Eledon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eledon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.